肺癌
医学
癌症
肿瘤科
回顾性队列研究
内科学
表皮生长因子受体
化疗
胃肠病学
作者
Chiara Catania,Stephen V. Liu,Marina Chiara Garassino,A. Delmonte,Vieri Scotti,F. Cappuzzo,C. Genova,Alessandro Russo,Marco Russano,Chiara Bennati,Ida Colantonio,Stefania Martini,Miguel Antonio Agüero Pino,Fabio Conforti,Laura Pala,G. Minuti,F. Citarella,Emanuela Olmetto,Alessandra Esposito,Priscilla Cascetta
出处
期刊:ESMO open
[Elsevier BV]
日期:2025-06-24
卷期号:10 (7): 105326-105326
被引量:31
标识
DOI:10.1016/j.esmoop.2025.105326
摘要
BACKGROUND: Histological transformation to small-cell lung cancer (SCLC) is an under-recognized but clinically relevant mechanism of resistance in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). While platinum-based chemotherapy (CT) has emerged as standard treatment after small-cell transformation, optimal treatment strategies are not defined, particularly with regard to the role of immune checkpoint inhibitors (ICIs) or continuation of EGFR-tyrosine kinase inhibitors (TKIs). MATERIALS AND METHODS: We conducted an international, retrospective, observational study on patients with EGFR-mutated NSCLC that transformed to SCLC, focusing on treatment and outcomes. RESULTS: Twenty-five patients across 11 centers were included. Twenty-four changed systemic treatment following SCLC transformation: CT (12 patients), CT plus EGFR-TKI (5 patients), CT plus ICI (6 patients), or CT plus ICI plus EGFR-TKI (1 patient). Median follow-up was 9 months (range 1-45 months). All patients experienced relapse with a median progression-free survival of 2 months [95% confidence interval (CI) 2-3 months] and 23 patients died, with a median overall survival (OS) of 9 months (95% CI 7-16 months). Median OS was comparable between patients treated with CT alone [9.5 months; 95% CI 5 months-not reached (NR)], CT plus EGFR-TKI (8 months; 95% CI 8 months-NR), and CT plus ICI (10 months; 95% CI 7 months-NR). Three patients survived >24 months from SCLC transformation; these patients were treated with CT alone (one patient), CT plus EGFR-TKI (one patient), and CT plus ICI and EGFR-TKI (one patient). OS was longer if SCLC transformation occurred >12 months from initial NSCLC diagnosis (19 patients) versus those with transformation within 12 months (6 patients): 31 versus 8 months (P < 0.001). CONCLUSIONS: The prognosis of patients with transformed SCLC remains poor, with only a minority achieving meaningful survival. Survival was similar in patients treated with CT alone or with the addition of ICI or EGFR-TKI. A time interval >12 months between NSCLC diagnosis and SCLC transformation was associated with longer survival and may reflect a different biology than early transformation.
科研通智能强力驱动
Strongly Powered by AbleSci AI